Radionuclide liver and bone scanning in the evaluation of patients with endometrial carcinoma.
Staging bone scans or skeletal surveys were obtained of 97 patients with endometrial carcinoma. Of the 77 patients with Stage I or II disease, no metastases were identified at staging. Three patients in the entire series demonstrated bony metastases; all of these metastases were detectable by radionuclide bone scan and radiographic bone survey. Eighty-nine patients were examined with radionuclide liver/spleen scanning at the time of staging. Four of the 89 initial scans were interpreted as demonstrating hepatocellular disease, and all four patients had abnormal liver function studies. Only one patient demonstrated a possible hepatic metastasis at initial diagnosis. This patient also had abnormal liver function studies. Based on these results, bone surveys and radionuclide bone scans are not indicated as screening procedures in endometrial carcinoma. It is suggested that screening for liver metastases in patients with endometrial carcinoma is not warranted in patients with normal liver function studies.
D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary*; D002277:Carcinoma / Q000000981:diagnostic imaging / Q000473:pathology* / Q000556:secondary; D011756:Diphosphates; D004164:Diphosphonates; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary*; D009367:Neoplasm Staging; D011877:Radionuclide Imaging; D013455:Sulfur; D013667:Technetium; D013669:Technetium Tc 99m Medronate; D013671:Technetium Tc 99m Sulfur Colloid; D014594:Uterine Neoplasms / Q000473:pathology*
D011756:Diphosphates; D004164:Diphosphonates; D013671:Technetium Tc 99m Sulfur Colloid; D013455:Sulfur; D013667:Technetium; D013669:Technetium Tc 99m Medronate